Table 2.
Characteristics of the study population.
|
| ||||
|---|---|---|---|---|
| VARIABLE | TOTAL POPULATION (N = 629) | FEMALE (n = 448, 71.2%) | MALE (n = 181, 28.8%) | p-VALUE |
|
| ||||
| Age (mean, SD) | 43.5 (±11.2) | 42.3 (±10.5) | 46.7 (±12.0) | <0.001* |
|
| ||||
| Level of education (n,%) No school attended Primary education Secondary education Beyond secondary |
41 (6.5) 418 (66.5) 127 (20.2) 43 (6.8) |
36 (8.0) 309 (69) 81 (18.1) 22 (4.9) |
5 (2.8) 109 (60.2) 46 (25.4) 21 (11.6) |
0.03** |
|
| ||||
| Occupation status (n,%) Retired or unemployed Self-employed Employed |
87 (13.8) 429 (68.2) 113 (18) |
69 (15.4) 310 (69.2) 69 (15.4) |
18 (9.9) 119 (65.8) 44 (24.3) |
0.07** |
|
| ||||
| Relationship status (n,%) Single/never married Married/cohabiting Widowed |
117 (18.6) 256 (40.7) 152 (24.2) |
87 (19.4) 158 (35.3) 119 (26.6) |
30 (16.6) 98 (54.1) 33 (18.2) |
0.41** |
|
| ||||
| Insurance status (n,%) Yes |
90 (14.3) |
57 (12.7) |
33 (18.2) |
0.07** |
|
| ||||
| Facility name (n,%) Amana Sinza Temeke Mnazi Mmoja Bunju Vijibweni |
110 (17.5) 121 (19.2) 115 (18.3) 135 (21.5) 66 (10.5) 82 (13.0) |
84 (18.8) 84 (18.8) 79 (17.7) 97 (21.7) 52 (11.6) 52 (11.6) |
26 (14.4) 37 (20.4) 36 (19.9) 38 (21) 14 (7.7) 30 (16.6) |
0.19** |
|
| ||||
| ART regimen (n,%) TDF+3TC+DTG (TLD) Other |
559 (89) 69 (11) |
396 (88.4) 52 (11.6) |
163 (90.6) 17 (9.4) |
0.43** |
|
| ||||
| HIV viral load (n,%) ≤50 copies >50 copies |
544 (86.6) 84 (13.4) |
395 (88.2) 53 (11.8) |
149 (82.8) 31 (17.2) |
0.07** |
|
| ||||
| Years lived with HIV infection (median, IQR) | 6 (3–11) | 6 (3–11) | 5 (2–10) | 0.31* |
|
| ||||
| Duration on ART (median, IQR) in years | 5 (3–10) | 5 (3–10) | 4 (2–10) | 0.35* |
|
| ||||
| Adherence to ART (n,%) Poor adherence (score < 10) Good adherence |
77 (12.2) 552 (87.8) |
57 (12.7) 391 (87.3) |
20 (11.1) 161 (89) |
0.56** |
|
| ||||
| Alcohol use (past 30 days) (n,%) | 158 (25.1) | 108 (24.1) | 50 (27.6) | 0.34** |
|
| ||||
| Prevalent comorbidities (self-reported) (n,%) Cardiovascular diseases (MI or stroke) Hypertension Diabetes Hyperlipidemia |
69 (10.9) 67 (10.7) 19 (3.0) 7 (1.1) |
57 (12.7) 55 (12.3) 12 (2.7) 5 (1.1) |
12 (6.6) 12 (6.6) 7 (3.9) 2 (1.1) |
0.03** 0.04** 0.43** 1.0*** |
|
| ||||
| Medication use (Hypertension, diabetes, dyslipidemia) (n,%) Any treatment Antihypertensive medication Glucose lowering medication Lipid lowering medication |
31 (4.9) 22 (3.5) 10 (1.6) 2 (0.3) |
24 (5.4) 16 (3.6) 7 (1.6) 2 (0.5) |
7 (3.9) 6 (3.3) 3 (1.7) 0 (0.0) |
0.43* |
|
| ||||
| Lifestyle modification (n,%) Yes |
163 (25.8) |
11 (24.8) |
52 (28.7) |
0.31** |
|
| ||||
| Family history of CVD (n,%) Yes |
166 (26.4) |
136 (30.4) |
30 (16.6) |
<.001** |
|
| ||||
| Self-reported health status (medina, IQR) | 20 (19–22.5) | 20.3 (19–22.5) | 20.6 (19–22.5) | 0.40* |
|
| ||||
CVD: cardiovascular disease, SD: Standard deviation, TDF: Tenofovir, 3TC: Lamivudine, DTG: Dolutegravir, TLD: Tenofovir, Lamivudine, Dolutegravir.
Self-reported health status possible range 5–25.
* Student t-test, ** Chi-square test, *** Fisher’s exact test.